The Week in Review: China and Clinical Trials
During the last week, we confirmed that China will shorten its IND approval time by more than one half, reducing the target for approval to four months from a range of eight to twelve months. Also confirmed was that the US FDA will start accepting all-China data as a basis for approval of drugs (see story). The news will have the effect of increasing the allure of conducting clinical trials in China.